Although LMP2 serves as a major viral antigen for developing therapeutic vaccines and T-cell-based immunotherapies in NPC patients, the effects of targeting LMP2 on tumor suppression in native EBV-positive NPC cells are not well-defined. This evidence concerns the gene PSMB9 and neoplasm.